Vir Biotechnology (VIR) Shares Outstanding (Diluted Average) (2021 - 2026)
Vir Biotechnology's (VIR) quarterly Shares Outstanding (Diluted Average) came in at $147.4 million in Q1 2026, up 7.19% year-on-year from $137.5 million in Q1 2025, and up 6.38% quarter-over-quarter from $138.5 million in Q4 2025.
Vir Biotechnology (VIR) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Vir Biotechnology has disclosed Shares Outstanding (Diluted Average) across 6 years of filings, most recently posting $147.4 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $147.4 million, up 7.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $147.4 million (up 7.19% YoY), and the FY2025 annual result was $138.5 million, up 1.67% from the prior year.
- Shares Outstanding (Diluted Average) came in at $147.4 million for Q1 2026 at Vir Biotechnology, up from $138.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $147.4 million in Q1 2026 to a low of $133.6 million in Q1 2023.
- The 5-year median for Shares Outstanding (Diluted Average) is $135.7 million (2024), against an average of $136.5 million.
- Across the five-year window, Shares Outstanding (Diluted Average) fell 0.62% in 2023 and gained 7.19% in 2026, its largest moves.
- Vir Biotechnology's Shares Outstanding (Diluted Average) stood at $134.8 million in 2022, then declined by 0.5% to $134.1 million in 2023, then climbed by 1.58% to $136.2 million in 2024, then gained by 1.67% to $138.5 million in 2025, then rose by 6.38% to $147.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $147.4 million (Q1 2026), $138.5 million (Q4 2025), and $138.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 92.44 Mn |
| 10 | Vir Biotechnology | 1.27 Bn | 1.27 Bn | - | 147.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.36 Mn |
| Dec 31, 2025 | 138.52 Mn |
| Sep 30, 2025 | 138.29 Mn |
| Jun 30, 2025 | 138.45 Mn |
| Mar 31, 2025 | 137.47 Mn |
| Dec 31, 2024 | 136.25 Mn |
| Sep 30, 2024 | 136.06 Mn |
| Jun 30, 2024 | 136.22 Mn |
| Mar 31, 2024 | 135.28 Mn |
| Dec 31, 2023 | 134.13 Mn |
| Sep 30, 2023 | 134.29 Mn |
| Jun 30, 2023 | 133.81 Mn |
| Mar 31, 2023 | 133.55 Mn |
| Dec 31, 2022 | 134.81 Mn |
| Sep 30, 2022 | 134.96 Mn |
| Jun 30, 2022 | 134.64 Mn |
| Dec 31, 2021 | 133.44 Mn |